Human growth hormone therapy linked with pediatric tibial physeal avulsion fractures

According to published results, recombinant human growth hormone therapy was associated with increased risk for proximal tibial physeal avulsion fractures in pediatric patients.
Samuel A. Beber, MSc, and colleagues at Hospital for Special Surgery performed a case-control study of 132 pediatric patients (mean age, 13 years) who reported to a single institution for a tibial fracture between Feb. 1, 2016, and May 4, 2023. Researchers analyzed two 1:1 matched cohorts: 66 patients with proximal tibial physeal avulsion fractures and a control group of 66 patients with midshaft tibial fractures.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart